Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxonidine in Postural Tachycardia Syndrome
NCT04140721Phase 1Active, not recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Aug 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of moxonidine in postural orthostatic tachycardia syndrome (POTS) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Change in Orthostatic Symptom Burden at 2 weeks. Started Aug 2021; status: active, not recruiting.
02
Drugs
moxonidine
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT04140721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04140721.